Cas:1036028-15-5 5-Methyl-1-[(4-methylphenyl)sulfonyl]-1H-pyrrolo[2,3-b]pyridine manufacturer & supplier

Chemical Name:5-Methyl-1-[(4-methylphenyl)sulfonyl]-1H-pyrrolo[2,3-b]pyridine

CAS.NO:1036028-15-5

Synonyms:5-Methyl-1-propyl-1H-pyrazole-4-carbaldehyde;5-methyl-1-tosyl-1H-pyrrolo[2,3-b]pyridine

Molecular Formula:C₁₅H₁₄N₂O₂S

Molecular Weight:286.34900

HS Code:

Physical and Chemical Properties:

Melting point:N/A

Boiling point:N/A

Density:N/A

Index of Refraction:

PSA:60.34000

Exact Mass:286.07800

LogP:3.97090

Material Safety Information (Applicable for Hazard Chemicals)

RIDADR:

Packing Group:

Contact us for information like 5-Methyl-1-propyl-1H-pyrazole-4-carbaldehyde chemical properties,Structure,melting point,boiling point,density,molecular formula,molecular weight,5-methyl-1-tosyl-1H-pyrrolo[2,3-b]pyridine physical properties,toxicity information,customs codes,safety, risk, hazard and MSDS, CAS,cas number,5-Methyl-1-propyl-1H-pyrazole-4-carbaldehyde Use and application,5-methyl-1-tosyl-1H-pyrrolo[2,3-b]pyridine technical grade,usp/ep/jp grade.

Related News: From the three-month point onward, 84.5% of uMRD patients maintained that deep remission in the blood to the 12-month assessment. These data show the new combo can deliver “very durable remissions” for the vast majority of patients, Tendler said. 5-Methyl-1-[(4-methylphenyl)sulfonyl]-1H-pyrrolo[2,3-b]pyridine manufacturer The complete chemical and pharmaceutical industry chain consists of basic chemical raw materials, pharmaceutical intermediates, chemical raw materials and chemical preparations. 5-Methyl-1-[(4-methylphenyl)sulfonyl]-1H-pyrrolo[2,3-b]pyridine supplier From the three-month point onward, 84.5% of uMRD patients maintained that deep remission in the blood to the 12-month assessment. These data show the new combo can deliver “very durable remissions” for the vast majority of patients, Tendler said. 5-Methyl-1-[(4-methylphenyl)sulfonyl]-1H-pyrrolo[2,3-b]pyridine vendor Jo Soden, Co-managing Director of Retrogenix, said ��We look forward to working with Resonant to deconvolute the targets for their antibodies. Resonant��s innovative platform is delivering functional therapeutic candidates at rapid pace and we welcome the opportunity to identify the specific, biologically-relevant targets which will help progress these leads towards promising new therapies for patients with cancer.�� 5-Methyl-1-[(4-methylphenyl)sulfonyl]-1H-pyrrolo[2,3-b]pyridine factory Jo Soden, Co-managing Director of Retrogenix, said ��We look forward to working with Resonant to deconvolute the targets for their antibodies. Resonant��s innovative platform is delivering functional therapeutic candidates at rapid pace and we welcome the opportunity to identify the specific, biologically-relevant targets which will help progress these leads towards promising new therapies for patients with cancer.��